Cargando…

Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia

SIMPLE SUMMARY: To date, quantitative and comprehensive information summarizing the differences in the efficacy and safety of anti-CD19 chimeric antigen receptor (CAR) T-cells with CD28 co-stimulatory domains or 4-1BB co-stimulatory domains for the treatment of B-cell acute lymphoblastic leukemia (B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Lijuan, Chen, Junchao, Cai, Ruifen, Wang, Xinrui, Liu, Yixiao, Zheng, Qingshan, Li, Lujin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216493/ https://www.ncbi.nlm.nih.gov/pubmed/37345104 http://dx.doi.org/10.3390/cancers15102767

Ejemplares similares

Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors
por: Feucht, J., et al.
Publicado: (2020)

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2020)

Anti‐CLL1‐based CAR T‐cells with 4‐1‐BB or CD28/CD27 stimulatory domains in treating childhood refractory/relapsed acute myeloid leukemia
por: Pei, Kunlin, et al.
Publicado: (2023)

Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors
por: Muliaditan, Tamara, et al.
Publicado: (2021)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation
por: Halim, Leena, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia
por: Grover, Punita, et al.
Publicado: (2022)

4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2(nd) Generation Chimeric Antigen Receptor-Modified T Cells
por: Dai, Qiang, et al.
Publicado: (2020)

Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol
por: Tang, Xiao-Yi, et al.
Publicado: (2016)

Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma
por: Wang, Yitian, et al.
Publicado: (2019)

Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
por: Ville, Simon, et al.
Publicado: (2015)

Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
por: Wei, Guoqing, et al.
Publicado: (2017)

CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells
por: Mezősi-Csaplár, Marianna, et al.
Publicado: (2023)

Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy
por: Olguín-Contreras, Luis Felipe, et al.
Publicado: (2021)

T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival
por: Bonham, Catherine A., et al.
Publicado: (2019)

The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells
Publicado: (1991)

PSMA-Specific CAR-Engineered T Cells for Prostate Cancer: CD28 Outperforms Combined CD28-4-1BB “Super-Stimulation”
por: Zuccolotto, Gaia, et al.
Publicado: (2021)

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma
por: Ying, Zhitao, et al.
Publicado: (2019)

41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
por: Baroni, Matteo Libero, et al.
Publicado: (2020)

CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T cells
por: Guercio, Marika, et al.
Publicado: (2020)

Correction: 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Publicado: (2020)

Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
por: Liang, Zuyu, et al.
Publicado: (2020)

CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
por: Saoulli, Katina, et al.
Publicado: (1998)

Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia
por: Zhang, Cheng, et al.
Publicado: (2022)

Chimeric CTLA4-CD28-CD3z T Cells Potentiate Antitumor Activity Against CD80/CD86–Positive B Cell Malignancies
por: Lin, Shouheng, et al.
Publicado: (2021)

Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody
por: Chen, Ying, et al.
Publicado: (2017)

Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells
por: de Campos, Najla Santos Pacheco, et al.
Publicado: (2022)

Neonatal Treatment With Beta-Cell Stimulatory Agents Reduces the Incidence of Diabetes in BB Rats
por: Buschard, Karsten, et al.
Publicado: (2000)

CD28(−) and CD28(low)CD8(+) Regulatory T Cells: Of Mice and Men
por: Vuddamalay, Yirajen, et al.
Publicado: (2017)

Antibody and B7/BB1-mediated ligation of the CD28 receptor induces tyrosine phosphorylation in human T cells
Publicado: (1992)

A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
por: Wang, Yiyun, et al.
Publicado: (2020)

Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition
por: Condomines, Maud, et al.
Publicado: (2015)

Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens
por: Zhao, Yuan, et al.
Publicado: (2012)

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells
por: Hombach, Andreas A., et al.
Publicado: (2012)

Fine Tuning and Efficient T Cell Activation with Stimulatory aCD3 Nanoarrays
por: Matic, Jovana, et al.
Publicado: (2013)

Restoration of CD28 Expression in CD28(−) CD8(+) Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production
por: Topp, Max S., et al.
Publicado: (2003)

Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2023)

Triggering of lymphocytes by CD28, 4-1BB, and PD-1 checkpoints to enhance the immune response capacities
por: Kaviani, Elina, et al.
Publicado: (2022)

Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2023)

CD46 is a potent co-stimulatory receptor for expansion of human IFN-γ-producing CD8(+) T cells
por: Hansen, Aida S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_md3hliknen9jgliim711693eit